{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:43:09Z","timestamp":1793763789278,"version":"4.6.1"},"reference-count":22,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Lymphoma survivors have a significantly higher risk of developing second primary lymphoma than the general population; however, bidirectional risks of developing B- and T-cell lymphomas (BCLs and TCLs) specifically are less well understood. We used population-based cancer registry data to estimate the subtype-specific risks of second primary lymphoma among patients with first BCL (n = 288\u2009478) or TCL (n = 23\u2009747). We observed nearly fivefold increased bidirectional risk between BCL and TCL overall (TCL following BCL: standardized incidence ratio [SIR] = 4.7, 95% confidence interval [CI] = 4.2-5.2; BCL following TCL: SIR = 4.7, 95% CI = 4.1-5.2), but the risk varied substantially by lymphoma subtype. The highest SIRs were observed between Hodgkin lymphoma (HL) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) (PTCL-NOS following HL: SIR = 27.5; HL following PTCL-NOS: SIR = 31.6). Strikingly elevated risks also were notable for angioimmunoblastic T-cell lymphoma (AITL) and diffuse large B-cell lymphoma (DLBCL) (AITL following DLBCL: SIR = 9.7; DLBCL following AITL: SIR = 15.3). These increased risks were strongest within the first year following diagnosis but remained persistently elevated even at \u22655 years. In contrast, SIRs were &amp;lt;5 for all associations of TCL with chronic lymphocytic leukemia\/small lymphocytic lymphoma and follicular lymphoma. These patterns support etiologic heterogeneity among lymphoma subtypes and provide further insights into lymphomagenesis.<\/jats:p>","DOI":"10.1182\/blood.2020010497","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T19:29:19Z","timestamp":1617737359000},"page":"785-789","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma"],"prefix":"10.1182","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-2294","authenticated-orcid":false,"given":"Dai","family":"Chihara","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-2935","authenticated-orcid":false,"given":"Gra\u00e7a M.","family":"Dores","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD; and"},{"name":"Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9767-2310","authenticated-orcid":false,"given":"Lindsay M.","family":"Morton","sequence":"additional","affiliation":[{"name":"Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"issue":"33","key":"2021090215275403800_B1","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021090215275403800_B2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.bjc.6602654","article-title":"Second primary cancers among 109 000 cases of non-Hodgkin\u2019s lymphoma","volume":"93","author":"Brennan","year":"2005","journal-title":"Br J Cancer"},{"issue":"16","key":"2021090215275403800_B3","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: a population-based evaluation over 25 years","volume":"20","author":"Dores","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021090215275403800_B4","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaad.2019.07.075","article-title":"Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: a surveillance, epidemiology, and end results analysis","volume":"83","author":"Goyal","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2021090215275403800_B5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archderm.143.1.45","article-title":"Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts","volume":"143","author":"Huang","year":"2007","journal-title":"Arch Dermatol"},{"issue":"1","key":"2021090215275403800_B6","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.3324\/haematol.11269","article-title":"Sequential development of large B cell lymphoma in a patient with peripheral T-cell lymphoma","volume":"93","author":"Furlan","year":"2008","journal-title":"Haematologica"},{"issue":"7","key":"2021090215275403800_B7","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1200\/JCO.2001.19.7.2026","article-title":"Non-Hodgkin\u2019s lymphoma after\u00a0primary Hodgkin\u2019s disease in the German Hodgkin\u2019s Lymphoma Study Group: incidence, treatment, and prognosis","volume":"19","author":"Rueffer","year":"2001","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021090215275403800_B8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12185-008-0176-2","article-title":"Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma","volume":"88","author":"Weisel","year":"2008","journal-title":"Int J Hematol"},{"key":"2021090215275403800_B9","author":"National Cancer Institute"},{"key":"2021090215275403800_B10","volume-title":"SEER Cancer Statistics Review, 1975-2017","author":"Howlader","year":"2020"},{"issue":"48","key":"2021090215275403800_B11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jncimonographs\/lgu012","article-title":"Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Wang","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"48","key":"2021090215275403800_B12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jncimonographs\/lgu013","article-title":"Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Morton","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"48","key":"2021090215275403800_B13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jncimonographs\/lgu006","article-title":"Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Linet","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"48","key":"2021090215275403800_B14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jncimonographs\/lgu010","article-title":"Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Cerhan","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"15","key":"2021090215275403800_B15","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0000000000000428","article-title":"Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study","volume":"28","author":"Gibson","year":"2014","journal-title":"AIDS"},{"issue":"1","key":"2021090215275403800_B16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/bjc.2013.294","article-title":"Risk\u00a0of lymphoma subtypes after solid organ transplantation in the United States","volume":"109","author":"Clarke","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"2021090215275403800_B17","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s11899-015-0292-z","article-title":"The Epstein-Barr Virus (EBV) in T cell and NK cell lymphomas: time for a reassessment","volume":"10","author":"Gru","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"issue":"15","key":"2021090215275403800_B18","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.19.01937","article-title":"Impaired immune health in survivors of diffuse large B-cell lymphoma","volume":"38","author":"Shree","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021090215275403800_B19","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1158\/2159-8290.CD-18-1143","article-title":"TET2 deficiency sets the stage for B-cell lymphoma","volume":"8","author":"Shingleton","year":"2018","journal-title":"Cancer Discov"},{"issue":"7831","key":"2021090215275403800_B20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes [published correction appears in Nature. 2020;591:E27]","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"issue":"18","key":"2021090215275403800_B21","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J Clin Oncol"},{"issue":"31","key":"2021090215275403800_B22","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.2008.16.4061","article-title":"Comparison of referring and final pathology for patients with non-Hodgkin\u2019s lymphoma in the National Comprehensive Cancer Network","volume":"26","author":"LaCasce","year":"2008","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1182\/blood.2026035130","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/9\/785\/1820437\/bloodbld2020010497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/9\/785\/1820437\/bloodbld2020010497.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T15:30:06Z","timestamp":1630596606000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/9\/785\/475679\/The-bidirectional-increased-risk-of-B-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,4,1]]},"published-print":{"date-parts":[[2021,9,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020010497","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}